Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) – Pipeline Review, H2 2016’, provides in depth analysis on Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted pipeline therapeutics.

The report provides comprehensive information on the Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8)

The report reviews Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics and enlists all their major and minor projects

The report assesses Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Alveonix AG

Dompe Farmaceutici S.p.A.

Glenmark Pharmaceuticals Ltd.

RaQualia Pharma Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) Overview 6

Therapeutics Development 7

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Stage of Development 7

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Therapy Area 8

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Indication 9

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Pipeline Products Glance 10

Early Stage Products 10

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Companies 11

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Therapeutics Assessment 13

Assessment by Monotherapy/Combination Products 13

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Companies Involved in Therapeutics Development 19

Alveonix AG 19

Dompe Farmaceutici S.p.A. 20

Glenmark Pharmaceuticals Ltd. 21

RaQualia Pharma Inc. 22

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Drug Profiles 23

AVX-012 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Ax-10 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Ax-8 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

DFL-23448 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

RQ-00203078 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

RQ-00434739 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecule to Antagonize TRPM8 for Neuropathic Pain - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Antagonize TRPM8 for Pain - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Dormant Projects 31

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Products under Development by Companies, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 13

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Alveonix AG, H2 2016 19

Pipeline by Dompe Farmaceutici S.p.A., H2 2016 20

Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 21

Pipeline by RaQualia Pharma Inc., H2 2016 22

Dormant Projects, H2 2016 31

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy/Combination Products, H2 2016 13

Number of Products by Mechanism of Actions, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 14

Number of Products by Routes of Administration, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 18

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports